HIV-1 protease inhibitors: their development, mechanism of action and clinical potential - Pillay, Bryant, et al. - 1995 () Citation Context ...sation of virus propagation. Because of recent advances in peptidomimetic chemistry, novel orally bioavailable inhibitors of the HIV protease have been ...
Other ideas for treatments include using protease inhibitors to kill the virus, or stopping it from binding to the ACE2 receptors on human cells. Michele Cohen Marill, WIRED, 28 Apr. 2020 The challenges that remain By the late 1990s, the availability of protease inhibitors led AIDS death rates...
Over the past 10 years, protease inhibitors have been a key component in antiretroviral therapies for HIV/AIDS. While the vast majority of HIV/AIDS cases in the world are due to HIV-1, HIV-2 infection must also be addressed. HIV-2 is endemic to Western Africa, and has also appeared in...
The discovery of human immunodeficiency virus (HIV) protease inhibitors is an example in which pharmacokinetic evaluation was implemented early in the disc... JH Lin - 《Advanced Drug Delivery Reviews》 被引量: 70发表: 1997年 The management of HIV-1 protease inhibitor pharmacokinetic interactions Th...
HIV- 1 protease inhibitors ( PIs) may improve hematopoietic functions owing to their direct effects on bone marrow ( BM) progenitor cells. In this study we investigated this hypothesis evaluating the effect of adding ritonavir ( RTV) and indinavir ( IND) on hematopoietic colony formation assays ...
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent Transposition of the pyridyl nitrogen from the P3 substituent to the P1′ substituent in HIV-1 protease inhibitors (PI) affords compounds such as 3 with an......
HIV PROTEASE INHIBITORS 专利名称：HIV PROTEASE INHIBITORS 发明人：ALBIZATI, Kim, F.,REICH, Siegfried,VARNEY, Michael, D.,ZHANG, Kanyin, E.,KOBAYASHI,Takuo 申请号：EP98910300.7 申请日：19980312 公开号：EP0970055A2 公开日：20000112 专利内容由知识产权出版社提供 摘要：Hiv protease inhibitor can ...
The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy Retroviral protease inhibitors used as therapy for HIV-1 infection have been causally associated with serious metabolic side effects, including peripheral ... H Murata,PW Hruz,M Mueckler - 《Journal of Biological Chemistry》...
THE PRESENT INVENTION REFERS TO NEW FORMULA I HIV INHIBITORS, PHARMACEUTICAL FORMS CONTAINING THESE COMPOUNDS AND METHODS OF TREATMENT AND / OR PREVENTION ... LN Jungheim,SW Kaldor,TE Mabry,... 被引量: 0发表: 1997年 HIV protease inhibitors, useful for the treatment of AIDS THE PRESENT INVENT...
In the second phase of our study, a structure-based five feature pharmacophore hypothesis was generated which signifies the importance of hydrogen bond donor, hydrogen bond acceptors and hydrophobic interaction between the HIV-1 protease enzyme and its inhibitors. This work has taken a significant ...